Table 3.
Patients with disconcordant miTNM stages
| ΔmiTNM | Indication | ADT | GSC | RPx | RTX | PSA | Device | [18F]-F-PSMA-1007 | [68Ga]-Ga-PSMA-11 | miTNM |
|---|---|---|---|---|---|---|---|---|---|---|
| T | BCR | Naive | 6 | No | Seeds | 4.99 | PET/CT | T0 | TR | N0M0 |
| PS | Naive | 8 | No | No | 13.80 | PET/CT | T2u | T2m | N0M0 | |
| BCR | Naive | 9 | Yes | No | 1.98 | PET/CT | TR | T0 | N0M0 | |
| BCR | Ended | 7 | Yes | Yes | 2.04 | PET/CT | TR | T0 | N1M1a | |
| BCR | Naive | 9 | Yes | No | 0.63 | PET/CT | T0 | TR | N1M0 | |
| N | BCR | Naive | 7 | Yes | Yes | 3.09 | PET/CT | N2 | N1 | TRM1c |
| FU | Naive | 7 | Yes | No | 4.40 | PET/CT | N2 | N1 | T0M0 | |
| PS | Naive | 7 | No | No | 113.70 | PET/CT | N2 | N1 | T3bM0 | |
| M | BCR | Naive | 9 | Yes | No | 0.58 | PET/CT | M1b | M0 | T0N1 |
ADT, androgen depriving therapy; GSC, Gleason Score, RPx, radical prostatectomy RTx, radiotherapy, BCR, biochemical recurrence; PS, primary staging; FU, follow-up; T2u (unifocal) T2m (multifocal), TR (local recurrence). Clinical consensus was made on the bold stage